Literature DB >> 10172048

A comparison of the safety, timing and cost-effectiveness of administering antibiotics by intravenous bolus (push) versus intravenous piggyback (slow infusion) in surgical prophylaxis.

J C Garrelts1, D F Smith, D Ast, J D Peterie.   

Abstract

This study was carried out to evaluate the safety, timing and cost-effectiveness of administering perioperative antimicrobial prophylaxis with cefmetazole via intravenous (IV) bolus, or 'push', compared with the more common method of IV 'piggyback' administration. A total of 60 patients were studied, 30 in each group. No major adverse reactions were noted in either group. Phlebitis did not occur with either method of administration. Loss of patency was noted in 2 patients in the IV bolus group at the time of catheter removal. While no overall difference in timing of antibiotic administration in relation to the surgical procedure was noted, 2 patients in the IV piggyback group did not receive their preoperative dose until after surgery had started. Both pharmacy preparation time and nursing administration time were shorter with the IV push method, resulting in a cost avoidance of $US0.60 per dose. Material cost avoidance, primarily due to elimination of the minibag and IV tubing with bolus administration, was $US3.25 per dose. Extrapolated cost avoidance for our institution, for both prophylaxis and treatment, is $US184 000 per year. Administration of selected antibiotics by IV push is safe, allows optimal timing of administration, minimises preparation and administration time, and is cost-effective. Hospitals and outpatient care facilities should consider this alternative method of antibiotic administration.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 10172048     DOI: 10.2165/00019053-199201020-00008

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  9 in total

1.  Pharmacist monitoring of the timing of preoperative antibiotic administration.

Authors:  C D Peterson; N J Schultz; D E Goldberg
Journal:  Am J Hosp Pharm       Date:  1990-02

2.  Intravenous therapy team and peripheral venous catheter-associated complications. A prospective controlled study.

Authors:  J W Tomford; C O Hershey; C E McLaren; D K Porter; D I Cohen
Journal:  Arch Intern Med       Date:  1984-06

3.  Hazards of peripheral intravenous lines.

Authors:  J Turnidge
Journal:  Med J Aust       Date:  1984-07-07       Impact factor: 7.738

4.  Factors determining peripheral vein tolerance to amino acid infusions.

Authors:  R Gazitua; K Wilson; B R Bistrian; G L Blackburn
Journal:  Arch Surg       Date:  1979-08

5.  Peripheral vein infusion of dextrose/amino acid solutions +/- 20% fat emulsion.

Authors:  J M Daly; E Masser; L Hansen; J E Canham
Journal:  JPEN J Parenter Enteral Nutr       Date:  1985 May-Jun       Impact factor: 4.016

6.  Infusion phlebitis associated with a programmable syringe-pump system versus gravity-feed minibottles.

Authors:  R J Baptista; D F Driscoll; J A Gallagher; E O'Keefe; G J Dumas; S M Hammer; P P Pacella
Journal:  Clin Pharm       Date:  1987-04

7.  Postinfusion phlebitis after intravenous push versus intravenous piggyback administration of antimicrobial agents.

Authors:  J C Garrelts; D Ast; J LaRocca; D F Smith; J D Peterie
Journal:  Clin Pharm       Date:  1988-10

8.  Peripheral vein complications in patients receiving amino acid/dextrose solutions.

Authors:  E L Massar; J M Daly; E M Copeland; D E Johnson; A C VonEshenbach; D Johnston; B Rundell; S J Dudrick
Journal:  JPEN J Parenter Enteral Nutr       Date:  1983 Mar-Apr       Impact factor: 4.016

9.  Postinfusion phlebitis associated with a syringe system versus minibags.

Authors:  R P Rapp; P Powers; V Tolbert; J J Piecoro; K E Record
Journal:  Clin Pharm       Date:  1986-05
  9 in total
  5 in total

Review 1.  Oral ciprofloxacin: a pharmacoeconomic evaluation of its use in the treatment of serious infections.

Authors:  J A Balfour; D Faulds
Journal:  Pharmacoeconomics       Date:  1993-05       Impact factor: 4.981

Review 2.  Cost-effective treatment of lower respiratory tract infections.

Authors:  J C Garrelts; A M Herrington
Journal:  Pharmacoeconomics       Date:  1996-07       Impact factor: 4.981

3.  Ceftriaxone. A pharmacoeconomic evaluation of its use in the treatment of serious infections.

Authors:  R Davis; H M Bryson
Journal:  Pharmacoeconomics       Date:  1994-09       Impact factor: 4.981

Review 4.  Teicoplanin. A pharmacoeconomic evaluation of its use in the treatment of gram-positive infections.

Authors:  C M Spencer; H M Bryson
Journal:  Pharmacoeconomics       Date:  1995-04       Impact factor: 4.981

5.  Meropenem. A pharmacoeconomic review of its use in serious infections.

Authors:  S M Holliday; P Benfield
Journal:  Pharmacoeconomics       Date:  1998-03       Impact factor: 4.981

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.